摘要
近年来,以表皮生长因子受体酪氨酸激酶抑制剂为代表的晚期非小细胞肺癌靶向治疗取得实质性进展。靶向治疗在提高病人生存率、改善生活质量方面有重要的作用。晚期非小细胞肺癌靶向治疗的靶点、药物和相关研究正以多元化的形式不断推陈出新,本文将简要综述当前晚期非小细胞肺癌靶向治疗的重大研究进展。
Recently, as a representative of targeted therapy, epidermal growth {actor receptor-tyrosine kinase inhibitors （EGFR-TKIs） in advanced non-small-cell lung cancer （NSCLC） have made substantial progress. Targeted therapy has important roles in improving survival rate and quality of life of the patients. Targets, drugs and related researches of targeted therapy in NSCLC are innovating in diversified forms. Current major research progress of targeted therapy in NSCLC will be briefly reviewed in the article.
出处
《药学服务与研究》
CAS
CSCD
2012年第3期166-171,共6页
Pharmaceutical Care and Research
关键词
非小细胞肺癌
靶向治疗
综述
non-small-cell lung cancer
targeted therapy
review
